PMC:7311890 / 22167-22388 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T151","span":{"begin":56,"end":59},"obj":"Body_part"},{"id":"T152","span":{"begin":136,"end":142},"obj":"Body_part"},{"id":"T153","span":{"begin":143,"end":148},"obj":"Body_part"}],"attributes":[{"id":"A151","pred":"fma_id","subj":"T151","obj":"http://purl.org/sig/ont/fma/fma85436"},{"id":"A152","pred":"fma_id","subj":"T152","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A153","pred":"fma_id","subj":"T153","obj":"http://purl.org/sig/ont/fma/fma67264"}],"text":"Changes in phospholipidome (i.e., reductions in PCs and PIs and increases in PEs) observed in COVID-19 corroborated a previous study on plasma lipid alterations in EVD fatalities compared to survivors (Kyle et al., 2019)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T112","span":{"begin":94,"end":102},"obj":"Disease"},{"id":"T113","span":{"begin":164,"end":167},"obj":"Disease"}],"attributes":[{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A113","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0005737"}],"text":"Changes in phospholipidome (i.e., reductions in PCs and PIs and increases in PEs) observed in COVID-19 corroborated a previous study on plasma lipid alterations in EVD fatalities compared to survivors (Kyle et al., 2019)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T211","span":{"begin":116,"end":117},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T212","span":{"begin":136,"end":142},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"}],"text":"Changes in phospholipidome (i.e., reductions in PCs and PIs and increases in PEs) observed in COVID-19 corroborated a previous study on plasma lipid alterations in EVD fatalities compared to survivors (Kyle et al., 2019)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T254","span":{"begin":56,"end":59},"obj":"Chemical"},{"id":"T256","span":{"begin":143,"end":148},"obj":"Chemical"}],"attributes":[{"id":"A254","pred":"chebi_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/CHEBI_53232"},{"id":"A255","pred":"chebi_id","subj":"T254","obj":"http://purl.obolibrary.org/obo/CHEBI_28874"},{"id":"A256","pred":"chebi_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/CHEBI_18059"}],"text":"Changes in phospholipidome (i.e., reductions in PCs and PIs and increases in PEs) observed in COVID-19 corroborated a previous study on plasma lipid alterations in EVD fatalities compared to survivors (Kyle et al., 2019)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"660","span":{"begin":143,"end":148},"obj":"Chemical"},{"id":"687","span":{"begin":94,"end":102},"obj":"Disease"},{"id":"688","span":{"begin":164,"end":167},"obj":"Disease"}],"attributes":[{"id":"A660","pred":"tao:has_database_id","subj":"660","obj":"MESH:D008055"},{"id":"A687","pred":"tao:has_database_id","subj":"687","obj":"MESH:C000657245"},{"id":"A688","pred":"tao:has_database_id","subj":"688","obj":"MESH:D019142"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Changes in phospholipidome (i.e., reductions in PCs and PIs and increases in PEs) observed in COVID-19 corroborated a previous study on plasma lipid alterations in EVD fatalities compared to survivors (Kyle et al., 2019)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T151","span":{"begin":0,"end":221},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Changes in phospholipidome (i.e., reductions in PCs and PIs and increases in PEs) observed in COVID-19 corroborated a previous study on plasma lipid alterations in EVD fatalities compared to survivors (Kyle et al., 2019)."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T470","span":{"begin":11,"end":26},"obj":"CHEBI:16247;CHEBI:16247"},{"id":"T471","span":{"begin":94,"end":102},"obj":"SP_7"},{"id":"T472","span":{"begin":136,"end":142},"obj":"UBERON:0001969"},{"id":"T473","span":{"begin":143,"end":148},"obj":"CHEBI:18059;CHEBI:18059"},{"id":"T76638","span":{"begin":29,"end":34},"obj":"SP_6;NCBITaxon:9606"},{"id":"T39490","span":{"begin":35,"end":43},"obj":"UBERON:0003215"},{"id":"T54175","span":{"begin":54,"end":61},"obj":"CL:0002212"},{"id":"T59433","span":{"begin":137,"end":142},"obj":"NCBITaxon:10239"},{"id":"T62411","span":{"begin":185,"end":190},"obj":"CHEBI:18059;CHEBI:18059"},{"id":"T83288","span":{"begin":205,"end":220},"obj":"CHEBI:18303;CHEBI:18303"}],"text":"Changes in phospholipidome (i.e., reductions in PCs and PIs and increases in PEs) observed in COVID-19 corroborated a previous study on plasma lipid alterations in EVD fatalities compared to survivors (Kyle et al., 2019)."}

{"project":"2_test","denotations":[{"id":"32610096-30808769-19699495","span":{"begin":215,"end":219},"obj":"30808769"}],"text":"Changes in phospholipidome (i.e., reductions in PCs and PIs and increases in PEs) observed in COVID-19 corroborated a previous study on plasma lipid alterations in EVD fatalities compared to survivors (Kyle et al., 2019)."}